Kahn Brothers Group Inc. DE increased its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 0.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,618,079 shares of the pharmaceutical company’s stock after buying an additional 13,065 shares during the period. GlaxoSmithKline comprises about 8.7% of Kahn Brothers Group Inc. DE’s holdings, making the stock its 5th biggest position. Kahn Brothers Group Inc. DE owned about 0.06% of GlaxoSmithKline worth $69,060,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Berman Capital Advisors LLC lifted its position in GlaxoSmithKline by 58.1% during the second quarter. Berman Capital Advisors LLC now owns 656 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares during the last quarter. Prestige Wealth Management Group LLC bought a new stake in GlaxoSmithKline during the second quarter valued at approximately $26,000. Financial Gravity Wealth Inc. lifted its position in GlaxoSmithKline by 62.7% during the second quarter. Financial Gravity Wealth Inc. now owns 799 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 308 shares during the last quarter. Manchester Financial Inc. bought a new stake in GlaxoSmithKline during the second quarter valued at approximately $39,000. Finally, Ellis Investment Partners LLC raised its stake in shares of GlaxoSmithKline by 144.5% during the third quarter. Ellis Investment Partners LLC now owns 1,022 shares of the pharmaceutical company’s stock worth $43,000 after acquiring an additional 604 shares in the last quarter. Institutional investors and hedge funds own 11.19% of the company’s stock.
Several research analysts have commented on GSK shares. Jefferies Financial Group reissued a “buy” rating on shares of GlaxoSmithKline in a research note on Thursday, August 29th. Cantor Fitzgerald raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating in a research note on Friday, October 11th. Citigroup reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Wednesday. Deutsche Bank reissued a “hold” rating on shares of GlaxoSmithKline in a research note on Thursday, October 31st. Finally, Goldman Sachs Group reissued a “buy” rating on shares of GlaxoSmithKline in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and four have issued a buy rating to the stock. GlaxoSmithKline presently has a consensus rating of “Hold” and a consensus target price of $41.79.
In other GlaxoSmithKline news, Director Plc Glaxosmithkline bought 177,777 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were purchased at an average price of $45.00 per share, for a total transaction of $7,999,965.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 10.00% of the company’s stock.
GlaxoSmithKline stock traded up $0.21 during mid-day trading on Friday, reaching $44.42. 2,020,375 shares of the company traded hands, compared to its average volume of 2,550,711. The company has a debt-to-equity ratio of 1.38, a current ratio of 0.82 and a quick ratio of 0.56. The firm’s 50 day moving average price is $42.90 and its 200 day moving average price is $41.10. The firm has a market capitalization of $110.42 billion, a price-to-earnings ratio of 14.06, a P/E/G ratio of 3.03 and a beta of 0.70. GlaxoSmithKline plc has a 52-week low of $36.41 and a 52-week high of $46.01.
GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings data on Wednesday, October 30th. The pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.10. GlaxoSmithKline had a net margin of 13.76% and a return on equity of 92.73%. The business had revenue of $11.57 billion for the quarter, compared to the consensus estimate of $11.34 billion. On average, sell-side analysts anticipate that GlaxoSmithKline plc will post 3.08 EPS for the current year.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More: Are all No-Load Funds Equal?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.